Overview Dividends

(RGEN) Repligen - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7599161095

Protein A Ligands, Chromatography Columns, Filtration Systems, Process Analytics

RGEN EPS (Earnings per Share)

EPS Growth (3Y CAGR): -13.25%
EPS Trend (3Y Correlation): -37.2%

RGEN Revenue

Revenue Growth (3Y CAGR): 0.40%
Revenue Trend (3Y Correlation): 18.4%

Description: RGEN Repligen November 04, 2025

Repligen Corporation (NASDAQ:RGEN) is a life-sciences firm that designs, manufactures, and sells bioprocessing technologies and systems across North America, Europe, and the Asia-Pacific. Its product portfolio includes Protein A affinity ligands, cell-culture growth factors, OPUS pre-packed and small-scale chromatography columns, filtration devices such as XCell ATF and TangenX cassettes, and process-analytics tools under the SoloVPE/FlowVPE brands. Customers span biopharma, diagnostics, academic labs, and contract manufacturing organizations, and the company maintains a partnership with Navigo Proteins GmbH to co-develop new affinity ligands.

Key recent metrics: FY 2023 revenue reached approximately $1.0 billion, with a gross margin near 70% and recurring consumable sales accounting for roughly 55% of total revenue-a sign of stable, repeatable demand. The bioprocessing market is being driven by a surge in biologics pipelines (projected CAGR ≈ 10% through 2028) and the shift toward single-use, high-throughput platforms that favor Repligen’s chromatography and filtration solutions. Additionally, the company’s cash conversion cycle has shortened to under 45 days, reflecting efficient working-capital management.

For a deeper quantitative dive, the ValueRay platform offers a granular breakdown of RGEN’s financial and operational metrics.

RGEN Stock Overview

Market Cap in USD	8,448m
Sub-Industry	Life Sciences Tools & Services
IPO / Inception	1990-03-26

RGEN Stock Ratings

Growth Rating	-39.4%
Fundamental	46.2%
Dividend Rating	-
Return 12m vs S&P 500	-16.0%
Analyst Rating	4.26 of 5

RGEN Dividends

Currently no dividends paid

RGEN Growth Ratios

Growth Correlation 3m	77.8%
Growth Correlation 12m	-44.8%
Growth Correlation 5y	-78.5%
CAGR 5y	-5.90%
CAGR/Max DD 3y (Calmar Ratio)	-0.12
CAGR/Mean DD 3y (Pain Ratio)	-0.22
Sharpe Ratio 12m	-0.28
Alpha	-15.09
Beta	1.085
Volatility	45.39%
Current Volume	679.9k
Average Volume 20d	1069k
Stop Loss	137.4 (-5.8%)
Signal	-0.14

Piotroski VR‑10 (Strict, 0-10) 2.5

Net Income (1.74m TTM) > 0 and > 6% of Revenue (6% = 42.5m TTM)

FCFTA 0.04 (>2.0%) and ΔFCFTA -0.66pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 87.86% (prev 166.1%; Δ -78.23pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.05 (>3.0%) and CFO 132.1m > Net Income 1.74m (YES >=105%, WARN >=100%)

Net Debt (-748.7m) to EBITDA (60.6m) ratio: -12.37 <= 3.0 (WARN <= 3.5)

Current Ratio 5.91 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (56.5m) change vs 12m ago -0.74% (target <= -2.0% for YES)

Gross Margin 36.64% (prev 46.88%; Δ -10.24pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 24.60% (prev 21.76%; Δ 2.84pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 0.97 (EBITDA TTM 60.6m / Interest Expense TTM 44.3m) >= 6 (WARN >= 3)

Altman Z'' 2.39

(A) 0.21 = (Total Current Assets 748.7m - Total Current Liabilities 126.8m) / Total Assets 2.92b

(B) 0.14 = Retained Earnings (Balance) 407.4m / Total Assets 2.92b

(D) 0.41 = Book Value of Equity 355.4m / Total Liabilities 856.9m

Total Rating: 2.39 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 46.20

1. Piotroski 2.50pt = -2.50

2. FCF Yield 1.24% = 0.62

3. FCF Margin 14.66% = 3.67

4. Debt/Equity 0.35 = 2.44

5. Debt/Ebitda -12.37 = 2.50

6. ROIC - WACC (= -8.04)% = -10.05

7. RoE 0.09% = 0.01

8. Rev. Trend 18.39% = 1.38

9. EPS Trend -37.21% = -1.86

What is the price of RGEN shares?

As of November 07, 2025, the stock is trading at USD 145.84 with a total of 679,858 shares traded.
Over the past week, the price has changed by -1.78%, over one month by -2.84%, over three months by +25.85% and over the past year by -0.08%.

Is Repligen a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Repligen (NASDAQ:RGEN) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 46.20 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of RGEN is around 136.99 USD . This means that RGEN is currently overvalued and has a potential downside of -6.07%.

Is RGEN a buy, sell or hold?

Repligen has received a consensus analysts rating of 4.26. Therefore, it is recommended to buy RGEN.

Strong Buy: 10
Buy: 4
Hold: 5
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the RGEN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	187	28.2%
Analysts Target Price	187	28.2%
ValueRay Target Price	154.1	5.7%

RGEN Fundamental Data Overview November 05, 2025

Market Cap USD = 8.45b (8.45b USD * 1.0 USD.USD)
P/E Trailing = 7508.5
P/E Forward = 74.0741
P/S = 11.9343
P/B = 3.9628
P/EG = 2.59
Beta = 1.085
Revenue TTM = 707.9m USD
EBIT TTM = 43.1m USD
EBITDA TTM = 60.6m USD
Long Term Debt = 525.6m USD (from longTermDebt, last fiscal year)
Short Term Debt = 15.1m USD (from shortTermDebt, last fiscal year)
Debt = 686.2m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -748.7m USD (from netDebt column, last quarter)
Enterprise Value = 8.39b USD (8.45b + Debt 686.2m - CCE 748.7m)
Interest Coverage Ratio = 0.97 (Ebit TTM 43.1m / Interest Expense TTM 44.3m)
FCF Yield = 1.24% (FCF TTM 103.8m / Enterprise Value 8.39b)
FCF Margin = 14.66% (FCF TTM 103.8m / Revenue TTM 707.9m)
Net Margin = 0.25% (Net Income TTM 1.74m / Revenue TTM 707.9m)
Gross Margin = 36.64% ((Revenue TTM 707.9m - Cost of Revenue TTM 448.5m) / Revenue TTM)
Gross Margin QoQ = 5.54% (prev 45.20%)
Tobins Q-Ratio = 2.87 (Enterprise Value 8.39b / Total Assets 2.92b)
Interest Expense / Debt = 4.00% (Interest Expense 27.4m / Debt 686.2m)
Taxrate = 12.86% (2.20m / 17.1m)
NOPAT = 37.6m (EBIT 43.1m * (1 - 12.86%))
Current Ratio = 5.91 (Total Current Assets 748.7m / Total Current Liabilities 126.8m)
Debt / Equity = 0.35 (Debt 686.2m / totalStockholderEquity, last fiscal year 1.97b)
Debt / EBITDA = -12.37 (Net Debt -748.7m / EBITDA 60.6m)
Debt / FCF = -7.21 (Net Debt -748.7m / FCF TTM 103.8m)
Total Stockholder Equity = 2.01b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.06% (Net Income 1.74m / Total Assets 2.92b)
RoE = 0.09% (Net Income TTM 1.74m / Total Stockholder Equity 2.01b)
RoCE = 1.70% (EBIT 43.1m / Capital Employed (Equity 2.01b + L.T.Debt 525.6m))
RoIC = 1.48% (NOPAT 37.6m / Invested Capital 2.54b)
WACC = 9.52% (E(8.45b)/V(9.13b) * Re(10.01%) + D(686.2m)/V(9.13b) * Rd(4.00%) * (1-Tc(0.13)))
Discount Rate = 10.01% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.63%
[DCF Debug] Terminal Value 75.32% ; FCFE base≈110.0m ; Y1≈135.7m ; Y5≈231.5m
Fair Price DCF = 49.82 (DCF Value 2.80b / Shares Outstanding 56.3m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -37.21 | EPS CAGR: -13.25% | SUE: 0.37 | # QB: 0
Revenue Correlation: 18.39 | Revenue CAGR: 0.40% | SUE: 2.59 | # QB: 3

Additional Sources for RGEN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle